SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) and VisionRenu Biomedical Technology Co., Ltd. have announced the signing of a Strategic Memorandum of Understanding (MOU) to collaborate in AI-powered biotechnology, precision medicine, and international capital market initiatives. The agreement positions both companies to participate in one of the world's fastest-growing technology sectors, as artificial intelligence continues to reshape the biotechnology industry.
Under the MOU, SUIC and VisionRenu will combine their strengths in medical technology innovation, commercialization, international business development, and access to U.S. capital markets. The collaboration is intended to accelerate VisionRenu's global expansion while creating long-term value through strategic financing, business development, and potential U.S. capital market opportunities. Both companies view the agreement as the first step toward building a long-term strategic partnership focused on innovation and sustainable growth.
Artificial Intelligence is rapidly transforming biotechnology by accelerating advances in gene editing, DNA synthesis, precision medicine, and digital biology. AI enables faster discovery of disease-related genes, improves CRISPR gene-editing precision, optimizes DNA and protein design, and significantly shortens the development cycle for next-generation therapeutics. Combined with automated DNA synthesis and robotic laboratories, AI is revolutionizing biological research through the Design-Build-Test-Learn (DBTL) platform, creating a new era of intelligent life science innovation.
Industry analysts expect AI-enabled biotechnology to become one of the world's largest innovation markets over the coming decades, creating multi-trillion-dollar opportunities across healthcare, drug discovery, synthetic biology, advanced manufacturing, and sustainable materials. Aligned with this global trend, SUIC's strategic collaboration with VisionRenu, together with partnerships involving AI biotechnology startups supported by Taiwan's Ministry of Health and Welfare (MOHW), positions the Company to expand into this rapidly growing sector. By leveraging AI, precision medicine, gene technologies, and international capital market resources, SUIC aims to accelerate innovation while building long-term shareholder value.
VisionRenu Biomedical Technology Co., Ltd. is a Taiwan-based medical technology company focused on research, development, manufacturing, and commercialization of innovative medical devices for brain health and ophthalmic care. Its flagship product, the MagRenu® Transcranial Magnetic Stimulation (TMS) System, is approved by Taiwan's TFDA for the treatment of depression. The company is also developing proprietary ophthalmic laser technologies designed to address the growing global demand for advanced vision care solutions. More information can be found at https://www.vision-renu.com/.
SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) is a technology-enabled investment and business acceleration company focused on acquiring and developing innovative businesses with high-growth potential. Through strategic investments, mergers and acquisitions, and access to international capital markets, SUIC supports portfolio companies in expanding globally and creating long-term shareholder value. For more information, visit https://sinounitedco.com/.
This press release contains forward-looking statements that involve risks and uncertainties. The Framework Agreement announced herein is non-binding, and there can be no assurance that any definitive transaction will be completed. Readers are cautioned not to place undue reliance on these forward-looking statements.
